(Q33875124)

29 July 2017

title

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine (English)

1 reference

29 July 2017

0 references

1 reference

3

Gerbes AL

1 reference

29 July 2017

Gülberg V

1

1 reference

29 July 2017

Bilzer M

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

30

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

870-875

1 reference

Pathogenesis and management of the hepatorenal syndrome

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Pathophysiology and treatment of ascites and the hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Response to Dopamine Hydrochloride in the Hepatorenal Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Low-dose ornipressin improves renal function in the hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Sustained effects of ornipressin in hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Functional renal failure in cirrhosis. Recovery after portacaval shunt

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300430

7 January 2021

Identifiers

DOI

10.1002/HEP.510300430

1 reference

29 July 2017

1 reference